From: Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
Cases (%)
Cumulative percentage (%)
Complete response
2 (3.1)
3.1
Partial response
8 (12.5)
15.6 (ORR)
Stable disease
14 (21.9)
37.5 (DCR)
Progressive disease
36 (56.3)
93.8
Unknown
4 (6.3)
100
Total
64 (100)